The Increase in Thyroid Cancer Incidence During the Last Four Decades Is Accompanied by a High Frequency of BRAF Mutations and a Sharp Increase in RAS Mutations
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
CONTEXT: Thyroid cancer incidence rates in the United States and globally have increased steadily over the last 40 years, primarily due to a tripling of the incidence of papillary thyroid carcinoma (PTC). OBJECTIVE: The purpose of this study was to analyze trends in demographic, clinical, pathologic, and molecular characteristics of PTC from 1974 to 2009. DESIGN AND SETTING: We identified and histologically reviewed 469 consecutive cases of PTC from one US institution from 4 preselected periods (1974 to 1985, 1990 to 1992, 2000, and 2009) and assessed BRAF and RAS point mutations and RET/PTC rearrangements among 341 tumors ≥0.3 cm in size. Changes over time were analyzed using polytomous and binary logistic regression; all analyses were adjusted for age and sex. RESULTS: During this period, the median age of patients at diagnosis increased from 37 to 53 years (P < .001) and the percentage of microcarcinomas (≤1.0 cm) increased from 33% to 51% (P < .001), whereas extrathyroidal extension and advanced tumor stage decreased from 40% to 21% (P = .005) and from 43% to 28% (P = .036), respectively. Changes in tumor histopathology showed a decrease in classic PTC and an increase in the follicular variant (P < .001). The proportion of tumors with a BRAF mutation was stable (∼46%) but increased from 50% to 77% (P = .008) within classic papillary PTCs. The proportion of tumors with RAS mutations increased from 3% to 25% and within follicular pattern tumors from 18% to 44% (P < .001). The proportion of RET/PTC rearrangements decreased from 11% to 2% (P = .038). CONCLUSIONS: Similar to US national trends, we found an increasing age at diagnosis and greater detection of smaller-sized intrathyroidal PTCs. However, the overall proportion of BRAF mutations remained stable. Sharply rising percentages of the follicular variant histology and RAS mutations after 2000 suggest new and more recent etiologic factors. The increased incidence is not likely to be due to environmental or therapeutic radiation because the percentage of RET/PTC rearrangements decreased.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
(2017) · Springer eBooks · doi:10.1007/978-3-319-40618-3 · Cited by 17,242
Siegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
Egner, J. R. (2010) · JAMA · doi:10.1001/jama.2010.1525 · Cited by 5,997
Increasing Incidence of Thyroid Cancer in the United States, 1973-2002
Davies, L., & Welch, H. G. (2006) · JAMA · doi:10.1001/jama.295.18.2164 · Cited by 3,369
Cox, D. R., & Hinkley, D. V. (1974) · doi:10.1007/978-1-4899-2887-0 · Cited by 3,089
Thyroid Cancer after Exposure to External Radiation: A Pooled Analysis of Seven Studies
Ron, E., Lubin, J. H., Shore, R. E., Mabuchi, K., Modan, B., Pottern, L. M., Schneider, A. B., Tucker, M. A., & Boice, J. D. (2012) · Radiation Research · doi:10.1667/rrav05.1 · Cited by 1,124
Self-citationThyroid Cancer after Exposure to External Radiation: A Pooled Analysis of Seven Studies
Ron, E., Lubin, J. H., Shore, R. E., Mabuchi, K., Modan, B., Pottern, L. M., Schneider, A. B., Tucker, M. A., & Boice, J. D. (1995) · Radiation Research · doi:10.2307/3579003 · Cited by 1,107 · cited 2×
“is a well-established risk factor for thyroid cancer (10, 11),”
BackgroundSelf-citationMolecular genetics and diagnosis of thyroid cancer
Nikiforov, Y. E., & Nikiforova, M. N. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.142 · Cited by 1,011
Self-citationIncreasing incidence of differentiated thyroid cancer in the United States, 1988–2005
Chen, A. Y., Jemal, A., & Ward, E. M. (2009) · Cancer · doi:10.1002/cncr.24416 · Cited by 988
Cited by
Integrated Genomic Characterization of Papillary Thyroid Carcinoma
Agrawal, N., Akbani, R., Aksoy, B. A., Ally, A., Arachchi, H., Asa, S. L., Auman, J. T., Balasundaram, M., Balu, S., Baylin, S. B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.050 · Cited by 3,062
Self-citationTrends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013
Lim, H., Devesa, S. S., Sosa, J. A., Check, D., & Kitahara, C. M. (2017) · JAMA · doi:10.1001/jama.2017.2719 · Cited by 2,159
Nikiforov, Y. E., Seethala, R. R., Tallini, G., Baloch, Z. W., Basolo, F., Thompson, L. D. R., Barletta, J. A., Wenig, B. M., Al Ghuzlan, A., Kakudo, K., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0386 · Cited by 1,404
Self-citationThe changing incidence of thyroid cancer
Kitahara, C. M., & Sosa, J. A. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.110 · Cited by 1,051
TERT Promoter Mutations Are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas
Melo, M., da Rocha, A. G., Vinagre, J., Batista, R., Peixoto, J., Tavares, C., Celestino, R., Almeida, A., Salgado, C., Eloy, C., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3734 · Cited by 555
Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update
Gadelha, M. R., Kasuki, L., Lim, D. S. T., & Fleseriu, M. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00115 · Cited by 363
Davies, L., Morris, L. G. T., Haymart, M., Chen, A. Y., Goldenberg, D., Morris, J., Ogilvie, J. B., Terris, D. J., Netterville, J., Wong, R. J., et al. (2015) · Endocrine Practice · doi:10.4158/ep14466.dscr · Cited by 327
New Therapies for Advanced Thyroid Cancer
Laha, D., Nilubol, N., & Boufraqech, M. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00082 · Cited by 261
Epidemiology of Thyroid Cancer
Kitahara, C. M., & Schneider, A. B. (2022) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-21-1440 · Cited by 259
Berends, A. M. A., Buitenwerf, E., de Krijger, R. R., Veeger, N. J. G. M., van der Horst-Schrivers, A. N. A., Links, T. P., & Kerstens, M. N. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.01.015 · Cited by 257
The changing epidemiology of thyroid cancer: why is incidence increasing?
Vigneri, R., Malandrino, P., & Vigneri, P. (2015) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000148 · Cited by 253
Androgens, oestrogens and endometrium: a fine balance between perfection and pathology
Gibson, D. A., Simitsidellis, I., Collins, F., & Saunders, P. T. K. (2020) · Journal of Endocrinology · doi:10.1530/joe-20-0106 · Cited by 76
Metadata
- Authors
- Jung, C. K., Little, M. P., Lubin, J. H., Brenner, A. V., Wells, S. A., Sigurdson, A. J., & Nikiforov, Y. E.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2014-02-01
- Volume
- 99
- Issue
- 2
- Pages
- E276-E285
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2062836415
- Cited by
- 343
- References
- 40
- FWCI
- 19.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.